<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04914221</url>
  </required_header>
  <id_info>
    <org_study_id>JLP-2002-101-PK</org_study_id>
    <nct_id>NCT04914221</nct_id>
  </id_info>
  <brief_title>The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Replicate Crossover Study to Compare the Pharmacokinetics and Safety in Healthy Adult Volunteers Following Oral Administration of JLP-2002</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jeil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, single-dose, replicate crossover study to compare the&#xD;
      pharmacokinetics and safety in healthy adult volunteers following oral administration of&#xD;
      JLP-2002&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, single-dose, replicate crossover study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2021</start_date>
  <completion_date type="Actual">May 26, 2021</completion_date>
  <primary_completion_date type="Actual">May 26, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of JLP-2002</measure>
    <time_frame>Time Frame: 192 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of JLP-2002</measure>
    <time_frame>Time Frame: 192 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Overactive Bladder(OAB)</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I- comparator / Period II- comparator / Period III-JLP-2002</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I- comparator / Period II- -JLP-2002 / Period III- comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I- JLP-2002/ Period II- comparator / Period III- comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JLP-2002</intervention_name>
    <description>administration of JLP-2002</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_label>Group III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator</intervention_name>
    <description>administration of comparator</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_label>Group III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Those who are 19 years of age or older and 55 years of age&#xD;
&#xD;
          -  BMI 18.5 ~ 27.5 kg/m2&#xD;
&#xD;
          -  Those who voluntarily agrees in writing after hearing a sufficient explanation of the&#xD;
             purpose and procedure of the clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those with clinically significant diseases or a history of liver, kidney,&#xD;
             cardiovascular system, endocrine system, musculoskeletal system, respiratory system,&#xD;
             neuropsychiatric system, blood/oncology system, etc.&#xD;
&#xD;
          -  Those with a history of gastrointestinal diseases or surgery that may affect the&#xD;
             absorption of drugs&#xD;
&#xD;
          -  Those who donated whole blood within 60 days from the date of eligibility assessment,&#xD;
             or who donated component blood within 30 days&#xD;
&#xD;
          -  Those who do not have a medically recognized contraceptive intention or plan to&#xD;
             provide sperm from the screening date to 4 weeks from the last administration of the&#xD;
             investigational drug&#xD;
&#xD;
          -  Those whose blood AST, ALT, or GGT levels in the screening test exceeded 3 times the&#xD;
             upper limit of the reference range&#xD;
&#xD;
          -  Those who showed clinically significant results in the hepatitis B test, hepatitis C&#xD;
             test, HIV test, and syphilis test&#xD;
&#xD;
          -  In the case of women, those who do not show a negative response on the pregnancy test&#xD;
&#xD;
          -  Those who judged that the investigator is not suitable for participation in clinical&#xD;
             trials, such as showing clinically significant results in other screening tests&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>May 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

